glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Effects of on CKD in Patients With Type 2 Diabetes Glucagon‐like peptide‐1 receptor agonists and
Description
How glucagon-like is glucagon-like peptide-1
Front Endocrinol (Lausanne) 9
Some data suggest GIP may promote adiposity under certain metabolic conditions
Metabolic benefits beyond weight loss Weight loss is the headline, but both medications produce metabolic improvements that extend far beyond the number on the scale
A patient with exenatide-associated acute-on-chronic renal failure requiring hemodialysis
2012 Nov;98(2):271-84
